This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Twenty sites across the U.S. are the first to receive the BrainsWay Deep transcranial magnetic stimulation system (Deep TMS) for obsessive-compulsive disorder (OCD)
HACKENSACK, N.J., October 8, 2018 – BrainsWay Ltd. (TASE: BRIN), the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announced completion of the first shipment of its Deep TMS system for the treatment of OCD in adults.
“This first helmet shipment represents a major milestone in the launch of our Deep TMS system for U.S. patients who are suffering from OCD. These twenty locations will now supply a new non-invasive effective and safe treatment option that could provide a better quality of life for patients suffering from OCD,” said Yaacov Michlin, president and chief executive officer of BrainsWay. “Our OCD indication for TMS brings a new era of treatment for this population and we are looking forward to shipping more helmets out to additional locations across the nation.”
The twenty sites across the U.S. that received the new helmets include:
BrainsWay’s Deep TMS system is a best-in-class device designed to maximize electromagnetic stimulation of deep and broad brain regions. BrainsWay’s Deep TMS technology differs from that of other focal TMS devices in that it has broad applicability and can directly stimulate areas of the brain at a greater depth and breadth than any other TMS device on the market safely and efficiently. BrainsWay’s TMS system now directly targets previously unreachable areas of the brain with its proprietary coils, allowing it to effectively treat OCD as well.